2013 is panning out to be a strong year for $80 billion biotech giant Amgen ( AMGN). Shares of the firm have rallied nearly 23% year-to-date, outperforming the S&P 500 by a considerable margin, and that's on top of the 34% that shares increased during 2012. This week, AMGN is making news after finally getting the go-ahead to buy Onyx Pharmaceuticals ( ONXX) in a deal worth $10.4 billion. The crown jewel in the deal is Kyprolis, a cancer drug that's still in the early stages of its lifecycle.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts